Q2 2025 Management View Punit S. Dhillon, President and CEO, highlighted the imminent reporting of Phase IIa data for ...

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...

Strong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating ...